Although O6-BG opened up a new field for enhanced tumor chemotherapy, clinical studies showed that it also inhibits the AGT activity in normal cells, which in turn leads to a significant increase in the myelosuppressive effects and consequently reduces the chemotherapeutic effects of such drugs [25]. This evidence concerns the gene AGT and neoplasm.